

Oral Sessions

Friday, September 12, 2008, 09:10 – 11:15 hrs

Session: 01 Malignant glioma: second line treatments (I)
Room: Auditorium
Time: 09:10 - 10:10 hrs
Speaking time: 8´+2´
Chair: A.Brandes (*Italy*), M.Gil (*Spain*)

O01

Bevacizumab (B) plus irinotecan (I) in progressive temozolomide (T) refractory glioblastoma multiforme (GBM): a single center experience using a low dose regimen

G. Dresemann, A. Dresemann, A. Hobbold;

CTC-Standort Franz-Hospital, Dülmen, Germany.

O02

Evaluation of the early antiangiogenic activity of Sunitinib malate by perfusion CBF and CBV values from DSC-based perfusion in recurrent glioblastoma

C. Chaskis, M. Dujardin, A. Michotte, B. Neyns;

UZ Brussel, Brussels, Belgium.

O03

Tegwondo - development of a novel near-continuous dose-dense temozolomide regimen for the treatment of recurrent gliomas

H. M. Strik¹, J. H. Buhk², C. Bock³, M. Nitsche⁴, A. L. Hoffmann¹, A. Wrede⁵, C. Maros⁶, U. Kaiser⁷, M. Christmann⁸, B. Kaina⁸;

¹Department of Neurology, Göttingen, Germany, ²Department of Neuroradiology, Göttingen, Germany, ³Department of Neurosurgery, Göttingen, Germany, ⁴Department of Radiation Oncology, Göttingen, Germany, ⁵Department of Neuropathology, Göttingen, Germany, ⁶Department of Oncology, General Hospital, Vienna, Austria, ⁷Department of Oncology, Hildesheim, Germany, ⁸Department of Toxicology, Mainz, Germany.

O04

The Temozolomide RESCUE study: A Phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma

J. Perry¹, W. Mason², K. Belanger³, P. Kavan⁴, D. Fulton⁵, J. Easaw⁶, S. Kirby⁷, D. Macdonald⁸, C. Shields⁹, J. F. Pouliot¹⁰;

¹Odette Cancer Center and Sunnybrook Health Sciences Center, Toronto, ON, Canada, ²Princess Margaret Hospital, Toronto, ON, Canada, ³Hôpital Notre-Dame, Montreal, QC, Canada, ⁴Royal Victoria Hospital, Montreal, QC, Canada, ⁵Cross Cancer Institute, Edmonton, AB, Canada, ⁶Tom Baker Cancer Centre, Calgary, AB, Canada, ⁷QE II Health Sciences Centre, Halifax, NS, Canada, ⁸London Regional Cancer Program, London, ON, Canada, ⁹Hôpital Enfant-Jésus, Quebec City, QC, Canada, ¹⁰Schering Plough Canada, Kirkland, QC, Canada.

O05

Therapeutic efficacy and toxicity of local (Gliadel® wafer) and systemic intensified chemotherapy one week on/one week off in recurrent gliomas after surgical resection

C. Ewelt¹, J. Schroeteler¹, W. Stummer¹, J. Felsberg², H. Steiger¹, M. Sabel¹;

¹Department of Neurosurgery, Duesseldorf, Germany, ²Department of Neuropathology, Duesseldorf, Germany.

Friday, September 12, 2008, 09:10 – 11:15 hrs

O06

A phase II multicentric trial of fotemustine (FTM) in patients (pts) with recurrent/progressive glioblastoma after radiotherapy plus concomitant and/or adjuvant temozolomide : a GICNO (Gruppo Italiano Cooperativo di Neuro-Oncologia) study

A. A. Brandes¹, A. Tosoni¹, E. Franceschi¹, E. Mazza², A. Santoro³, M. Faedi⁴, R. Labianca⁵, R. Bertorelle⁶, T. Perrone⁷, E. Pesenti⁷;

¹Bellaria Maggiore Hospital, Bologna, Italy, ²San Raffaele Hospital, Milano, Italy, ³Istituto Clinico Humanitas, Rozzano, Italy, ⁴Ospedale Bufalini, Cesena, Italy, ⁵Ospedali Riuniti, Bergamo, Italy, ⁶Istituto Oncologico Veneto, Padova, Italy, ⁷Italfarmaco, Milano, Italy.

Session: 02 Surgery of gliomas
Room: Sala J
Time: 09:10 - 10:10 hrs
Speaking time: 8´+2´
Chair: C.Carapella (Italy), H.Duffau (France)

O07

Multimodal preoperative MR-imaging in patients with presumed low grade gliomas in eloquent language areas - implications for targeted surgical resection

R. Gerlach, E. Hattingen, K. Franz, T. Gasser, I. Kropf, A. Szelenyi, V. Seifert;
Johann Wolfgang Goethe- University, Frankfurt, Germany.

O08

Combined use of DTI FT and intraoperative subcortical mapping for surgical removal of gliomas

L. Bello¹, A. Castellano², G. Bertani¹, A. Gambin², A. Casarotti¹, A. Falini²;

¹Neurosurgery, University of Milano, Milano, Italy, ²Neuroradiology, University Vita e Salute, Milano, Italy.

O09

Surgery of insular WHO grade II gliomas: A consecutive series of 52 patients

H. Duffau;
Hôpital Gui de Chauliac, Montpellier, France.

O10

The impact of resection in the treatment of glioblastoma multiforme: Survival comparison with the RTOG recursive partitioning analysis of ALA glioma study patients

W. Stummer¹, U. Pichlmeier², G. Schackert³;

¹Department of Neurosurgery, Düsseldorf, Germany, ²Medac GmbH, Hamburg, Germany, ³Department of Neurosurgery, Universitätsklinikum Dresden, Germany.

O11

Combined use of tractography-integrated functional neuronavigation and 5-ALA fluorescence navigation during resection of glioblastoma multiforme involving pyramidal tract

K. Sato, T. Ito, M. Oikawa, H. Nakamura;
Nakamura Memorial Hospital, Sapporo, Japan.

O12

Surgery guided by 5-ALA fluorescence is a safe and efficient method with the potential for greatly increase the rate of gross total resection in glioblastoma

R. Diez Valle, S. Tejada Solis, M. Idoate Gastearena;
Clinica Universitaria de Navarra, Pamplona, Spain.

Session: 03 Experimental models of targeted therapies
Room: Sala F
Time: 09:10 - 10:10 hrs
Speaking time: 8´+2´
Chair: R.Galli (Italy), J.Seoane (Spain)

O13

CpG-oligonucleotides are superior to other TLR-ligands in the local treatment of established intracerebral murine gliomas

O. M. Grauer¹, J. W. Molling², R. P. M. Suttmüller³, S. Nierkens², G. J. Adema²;

¹Department of Neurology, University of Regensburg, Regensburg, Germany, ²Department of Tumorimmunology, NCMLS, Radboud University of Nijmegen, Nijmegen, The Netherlands, ³Organon NV, Target Discovery, Oss, The Netherlands.

O14

Inhibition of diffusely invasive glioblastoma growth in vivo by targeting EGFR but not VEGFR-2

K. Lamszus¹, T. Martens¹, Y. Laabs¹, H. Günther¹, L. Witte², M. Westphal¹;

¹Dept. of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ²ImClone Systems, New York, NY, United States.

O15

Differentiation therapy exerts anti-tumorigenic, anti-angiogenic, anti-invasive and proapoptotic effects in brain tumor stem cell-derived tumors

B. Campos¹, F. Wan¹, F. Zeppernick¹, R. Ahmadi¹, M. Farhadi¹, W. Roth², P. Beckhove³, A. Unterberg¹, B. Radlwimmer⁴, C. Herold-Mende¹;

¹Division of Neurosurgical Research, Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany, ²Molecular Neuro-Oncology, German Cancer Research Center, Heidelberg, Germany, ³Division of Tumor Immunology, German Cancer Research Center, Heidelberg, Germany, ⁴Division of Molecular Genetics, German Cancer Research Center, Heidelberg, Germany.

O16

Antiangiogenic treatment reduces tumor vasculature and tumor cell infiltration in a glioma cancer stem cell model in nude mice

L. Bello¹, **C. Verpelli¹**, G. Bertani¹, G. Casaceli¹, V. Lucini², R. Galli³, C. Sala⁴;

¹Neurosurgery, University of Milano, ELAT, Milano, Italy, ²Pharmacology, University of Milano, ELAT, Milano, Italy, ³Stem Cell Research Institute, DIBIT, HSR, Milano, Milano, Italy, ⁴Pharmacology, University of Milano, CNR, ELAT, Milano, Italy.

O17

Tumor specific migration of bone-marrow derived rat mesenchymal stem cells in the invasive N29 rat brain tumor model

D. Bexell^{1,2}, S. Gunnarsson^{1,2}, A. Tormin², D. Gisselsson³, S. Scheding², J. Bengzon^{1,2};

¹Clinical Sciences, Neurosurgery, Lund University, Lund, Sweden, ²Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, Sweden, ³Clinical Genetics, Lund University, Lund, Sweden.

O18

In vitro investigation of Varizella Zoster Virus as an oncolytic virus in glioblastoma therapy

N. Thon¹, H. Leske¹, C. Schichor¹, J. Tonn¹, R. Goldbrunner¹, A. Baiker²;

¹Department of Neurosurgery, Munich, Germany, ²Max von Pettenkofer Institute, Munich, Germany.

Session: 04 Malignant glioma: second line treatments (II)
Room: Auditorium
Time: 10:15 - 11:15 hrs
Speaking time: 8´+2´
Chair: M.Brada (United Kingdom), W.Wick (Germany)

O19

A multicenter stratified phase II study of cetuximab for the treatment of patients with recurrent high-grade glioma

B. Neyns¹, **J. Sadones**¹, **E. Joosens**², **F. Bouttens**³, **L. Verbeke**⁴, **J. Baurain**⁵, **L. Dhondt**⁶, **T. Strauven**⁷, **C. Chaskis**¹, **A. Michotte**¹;

¹UZ Brussel, Brussel, Belgium, ²Middelheim ZNA, Antwerpen, Belgium, ³AZ St. Lucas, Gent, Belgium, ⁴OLV Aalst, Aalst, Belgium, ⁵Cliniques Universitaires St. Luc, Bruxelles, Belgium, ⁶Centre Hospitalier Notre-Dame et Reine Fabiola, Charleroi, Belgium, ⁷AZ St. Augustinus, Antwerpen, Belgium.

O20

Phase II study of antineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma

S. R. Burzynski, **R. Weaver**, **T. Janicki**, **B. Szymkowski**, **M. Walczak**, **G. Burzynski**;
Burzynski Clinic, Houston, TX, United States.

O21

A randomised trial of procarbazine, CCNU and vincristine (PCV) vs temozolomide (5-day or 21-day schedule) for recurrent high grade glioma (Medical Research Council Trial BR12, ISRCTN83176944)

M. Brada for the **BR12 collaborators**;
Institute of Cancer Research, Sutton, United Kingdom.

O22

Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma (GBM): A phase III study

W. Wick¹, **V. K. Puduvall**², **M. Chamberlain**³, **A. Carpentier**⁴, **L. Cher**⁵, **W. Mason**⁶, **M. Van den Bent**⁷, **S. Hong**⁸, **D. Thornton**⁸, **H. Fine**⁹;

¹University of Heidelberg, Heidelberg, Germany, ²University of Texas, MD Anderson Cancer Center, Houston, TX, United States, ³H. Lee Moffitt Cancer Center, Tampa, FL, United States, ⁴Hopital Pitie Salpetriere, Paris, France, ⁵Austin Health, Victoria, Australia, ⁶Princess Margaret Hospital, Toronto, ON, Canada, ⁷Erasmus Medisch Centrum, Rotterdam, The Netherlands, ⁸Eli Lilly and Company, Indianapolis, IN, United States, ⁹National Cancer Institute, Bethesda, MD, United States.

O23

Targeted therapy with AP 12009 for recurrent or refractory high-grade glioma: results update of a Phase IIb study

U. Bogdahn¹, **A. K. Mahapatra**², **V. E. Oliushine**³, **C. Moul**⁴, **V. E. Parfenov**⁵, **G. Stockhammer**⁶, **S. Ludwig**⁷, **G. Wuerth**⁷, **H. Heinrichs**⁷, **K. H. Schlingensiepen**⁷;

¹Neurologische Universitätsklinik, Regensburg, Germany, ²All India Institute of Medical Sciences, New Delhi, India, ³Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation, ⁴National Institute of Mental Health and Neurosciences, Bangalore, India, ⁵Military Medical Academy, St. Petersburg, Russian Federation, ⁶Universitätsklinik Innsbruck, Innsbruck, Austria, ⁷Antisense Pharma, Regensburg, Germany.

O24

Phase I of high dose temozolomide (HDTMZ) with peripheral blood stem cell support (PBSCS) rescue in recurrent high grade glioma (HGG)

D. Frappaz¹, **S. Dussart**¹, **J. Pierga**², **J. Bay**³, **M. Fabbro**⁴, **L. Djafari**⁵, **M. Sunyach**¹;

¹Centre Léon Bérard, Lyon, France, ²Institut Curie, Paris, France, ³Centre Jean Perrin et CHU, Clermont-Ferrand, France, ⁴Centre Val D'Aurelle, Montpellier, France, ⁵Schering Plough, Levallois-Perret, France.

Session: 05 Low grade gliomas
Room: Sala J
Time: 10:15 - 11:15 hrs
Speaking time: 8´+2´
Chair: J.Rees (*United Kingdom*), O.Cruz (*Spain*)

O25

Targeting the *BRAF* oncogene in pediatric low-grade astrocytomas

S. M. Pfister¹, W. Janzarik², M. Remke³, A. Ernst³, A. Gnekow⁴, G. Reifenberger⁵, W. Scheurlen⁶, H. Omran⁷, A. Kulozik¹, P. Lichter³;

¹Department of Pediatric Hematology, Oncology and Immunology, Heidelberg, Germany, ²Department of Neurology, University Hospital Freiburg, Freiburg, Germany, ³German Cancer Research Center, Division Molecular Genetics, Heidelberg, Germany, ⁴Hospital for Children and Adolescents Augsburg, Augsburg, Germany, ⁵Department of Neuropathology, Heinrich-Heine-University, Düsseldorf, Germany, ⁶Cnopfsche Kinderklinik, Nürnberg, Germany, ⁷Department of Pediatric Neurology and Muscle Disorders, University Hospital Freiburg, Freiburg, Germany.

O26

MGMT promoter Hypermethylation in low grade Astrocytomas

M. Eoli, A. Di Stefano, L. Valletta, S. Guzzetti, D. Bianchessi, B. Pollo, A. Silvani, M. Bruzzone, A. Boiardi, G. Broggi, G. Finocchiaro;
C. Besta, Milan, Italy.

O27

Protracted low dose Temozolomide (TMZ) as initial treatment for progressive low grade oligodendroglial tumors: a phase II AINO (Italian Association for Neuro-Oncology) study

E. Trevisan¹, E. Laguzzi¹, D. Guarneri¹, C. Bompresz², M. Caroli³, B. Leoncini¹, R. Soffiatti¹, R. Rudà¹;

¹Neuro-Oncology Unit, Torino, Italy, ²University, Ancona, Italy, ³University, Milano, Italy.

O28

Tumour growth rate predicts transformation-free survival in adult low-grade gliomas

J. H. Rees^{1,2}, J. S. Winston^{1,2}, R. Jager^{1,2}, C. Benton¹, G. Brasil Caseiras^{1,2}, P. S. Tofts³, D. Altmann⁴, D. Tozer², A. D. Waldman^{5,6};

¹National Hospital for Neurology and Neurosurgery, London, United Kingdom, ²UCL Institute of Neurology, London, United Kingdom, ³Brighton and Sussex Medical School, Brighton, United Kingdom, ⁴London School of Hygiene and Tropical Medicine, London, United Kingdom, ⁵Imperial College, London, United Kingdom, ⁶Charing Cross Hospital, London, United Kingdom.

O29

Low grade astrocytoma in children: single institutional experience in 143 patients

O. Cruz, N. Perez, E. Rodriguez, M. Suñol, V. Cusi, C. De Torres, G. Garcia-Fructuoso, A. Guillen, A. Parareda, J. Mora;

Hospital St Joan de Deu, Esplugues de Llobregat, Barcelona, Spain.

O30

Temozolomide in primary gliomatosis cerebri: final results of a retrospective study of the AINO (Italian Association for Neuro-Oncology)

R. Rudà¹, E. Laguzzi¹, A. Pace², C. M. Carapella², M. Riva³, M. Salvati⁴, A. Silvan⁵, L. Fariselli⁵, M. Caroli⁶, R. Soffiatti¹;

¹Division of Neuro-Oncology, Torino, Italy, ²Cancer Center "Regina Elena", Rome, Italy, ³Division of Neurology, Lodi, Italy, ⁴Division of Neurosurgery "La Sapienza", Rome, Italy, ⁵Neurological Institute "C. Besta", Milano, Italy, ⁶Division of Neurosurgery "Policlinico", Milano, Italy.

Friday, September 12, 2008, 09:10 – 11:15 hrs

Session: 06 Non glial tumors
Room: Sala F
Time: 10:15 - 11:15 hrs
Speaking time: 8´+2´
Chair: A.Omuro (France), A.Navajas (Spain)

O31

Degree of Blood-Brain Barrier Disruption and Cumulative Total Dose Intensity in the Treatment of Primary Central Nervous System Lymphoma

D. F. Kraemer¹, L. Angelov², N. D. Doolittle³, T. Siegal⁴, D. Peereboom², K. Jahnke³, E. Shalom⁴, G. Barnett², J. McGregor⁵, E. A. Neuwelt³;

¹Oregon State University, Portland, OR, United States, ²Cleveland Clinic, Cleveland, OH, United States, ³Oregon Health & Science University, Portland, OR, United States, ⁴Hadassah Hebrew University Hospital, Jerusalem, Israel, ⁵Ohio State University, Columbus, OH, United States.

O32

Methotrexate, procarbazine and CCNU as chemotherapy-only treatment for primary central nervous system lymphoma in young patients: a French Neuro-Oncology Association (ANOCEF) study

A. M. P. Omuro¹, L. Taillandier², O. Chinot³, C. Carnin², M. Barrié³, C. Soussain⁴, M. Tanguy⁴, M. Sierra Del Rio⁴, V. Leblond⁴, K. Hoang-Xuan⁴;

¹Memorial Sloan-Kettering Cancer Center, New York, NY, United States, ²CHU Nancy, Nancy, France, ³CHU La Timone, Marseille, France, ⁴CHU Pitié-Salpêtrière, Paris, France.

O33

Early radiographic response to chemotherapy predicts favorable outcome in patients with primary CNS lymphoma

H. Pels¹, A. Juergens¹, I. Schirgens², A. Glasmacher², H. Schulz³, A. Engert³, V. Diehl³, M. Linnebank², G. Schackert⁴, H. Reichmann⁴, F. Kroschinsky⁴, M. Vogt-Schaden⁵, G. Egerer⁵, U. Bode², M. Deckert³, R. Fimmers², K. Fliessbach², T. Klockgether², I. G. H. Schmidt-Wolf², U. Schlegel¹;

¹Ruhr-Universität Bochum, Bochum, Germany, ²University of Bonn, Bonn, Germany, ³University of Cologne, Cologne, Germany, ⁴University of Dresden, Dresden, Germany, ⁵University of Heidelberg, Heidelberg, Germany.

O34

Primary Pineal Tumors. Outcome and prognostic factors. A study from the Rare Cancer Network (RCN)

S. Villà¹, R. Miller², M. Krengli³, H. Abusaris⁴, B. O. Baumert⁵, S. Servagi-Vernat⁶, S. Igdem⁷, A. Lucas⁸, S. Boluda⁹, R. O. Mirimanoff¹⁰;

¹HU Germans Trias. ICO Badalona, Badalona. Barcelona, Spain, ²Mayo Clinic, Rochester, MN, United States, ³Univ of Piemonte Orientale, Novara, Italy, ⁴Dr. N. Verbeeten Institute, Tilburg, Netherlands, ⁵Grow Research Institute. MAASTRO Clinic, Maastricht, Netherlands, ⁶University Hospital, Besançon, France, ⁷Metropolitan Hospital, Istanbul, Turkey, ⁸ICO DiR, Hospitalet, Spain, ⁹HU Bellvitge, Hospitalet, Spain, ¹⁰HU Vaudois, Lausanne, Switzerland.

O35

Metastatic medulloblastome Chang staging system revised

C. Dufour¹, J. Michell², A. Fourcade¹, A. Laplanche¹, C. Kalifa¹, D. Couanet¹, J. Grill¹;

¹Gustave Roussy, Villejuif, France, ²CHU, Amiens, France.

Friday, September 12, 2008, 09:10 – 11:15 hrs

O36

Atypical teratoid/rhabdoid tumors (AT/RTs) in the pediatric population of Austria: a population-based study, 1996 - 2006

A. Woehrer¹, T. Waldhoer², A. Azizi³, I. Leisser¹, T. Czech⁴, H. Budka¹, J. A. Hainfellner¹, I. Slavc³, C. Haberler¹, A. W. on behalf of the Austrian Brain Tumour Registry¹;

¹Institute of Neurology, Medical University of Vienna, Vienna, Austria, ²Center for Public Health, Department of Epidemiology, Medical University of Vienna, Vienna, Austria, ³Department of Pediatrics, Medical University of Vienna, Vienna, Austria, ⁴Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.